Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240918 | 0.84 | BTK (0.41) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL6236108 | 0.83 | BTK (0.47) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13719171 | 0.82 | MAP4K4 (0.45) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13719169 | 0.82 | MAP4K4 (0.45) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13876125 | 0.81 | BTK (0.48) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13719359 | 0.81 | MAP4K4 (0.47) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL13822690 | 0.81 | BTK (0.49) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL12517290 | 0.81 | BTK (0.49) | MAP4K4BTKJAK3AURKAPDPK1 | |
| SCHEMBL15682637 | 0.79 | DPP4 (0.51) | DPP4 | |
| SCHEMBL13822697 | 0.79 | MAP4K4 (0.45) | MAP4K4BTKJAK3AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522915-B2 | Method for preparing an important intermediate of linagliptin | 2Y-CHEM, LTD. (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | 2Y-CHEM, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | DPP4, DPP9, DPP3 | MAP4K4 1128/4885BTK 1471/4885JAK3 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.